TY - JOUR
T1 - The Organization of the Asthma Clinical Research Network
T2 - A multicenter, multiprotocol clinical trials team
AU - Kephart, Donna K.
AU - Chinchilli, Vernon M.
AU - Hurd, Suzanne S.
AU - Cherniack, Reuben M.
N1 - Funding Information:
This work was supported by grant no. U10HL51845, Division of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health.
Funding Information:
A unique challenge faced by the ACRN is supporting the simultaneous development and conduct of multiple protocols. Since most multicenter clinical trials funded by the National Institutes of Health focus on one study protocol for the duration of the funding period, the ACRN DCC was faced with developing operating systems to meet the challenge of supporting multiple studies, some carried out concurrently.
PY - 2001
Y1 - 2001
N2 - Asthma is an increasingly serious cause of morbidity and mortality in the United States, affecting approximately 12 million people, including men and women, children and adults, and all racial and ethnic groups. It is now recognized that asthma is a complex disease of varied etiology triggered by a number of factors such as allergens, drugs, chemicals, exercise, cold dry air, infections, and emotions. Asthma is a chronic disease requiring multiple medications to treat and control symptoms as well as medications thought to control the underlying inflammation. Despite major advances in understanding the etiology and pathophysiology of asthma and the development of new therapeutic modalities, the prevalence, severity, and mortality from asthma have all increased over the past decades in all age groups. Hospitalizations for asthma have doubled in adults and increased fivefold for children over the past 20 years. Mortality appears to be particularly high in urban and rural minority populations. Asthma continues to place a heavy burden on patients and their families as well as the health-care system. In an attempt to respond to the need for well-designed clinical trials to allow rapid evaluation of new and existing therapeutic approaches for asthma and for dissemination of laboratory and clinical findings to the health-care community, the Division of Lung Diseases, National Heart, Lung, and Blood Institute, established the Asthma Clinical Research Network.
AB - Asthma is an increasingly serious cause of morbidity and mortality in the United States, affecting approximately 12 million people, including men and women, children and adults, and all racial and ethnic groups. It is now recognized that asthma is a complex disease of varied etiology triggered by a number of factors such as allergens, drugs, chemicals, exercise, cold dry air, infections, and emotions. Asthma is a chronic disease requiring multiple medications to treat and control symptoms as well as medications thought to control the underlying inflammation. Despite major advances in understanding the etiology and pathophysiology of asthma and the development of new therapeutic modalities, the prevalence, severity, and mortality from asthma have all increased over the past decades in all age groups. Hospitalizations for asthma have doubled in adults and increased fivefold for children over the past 20 years. Mortality appears to be particularly high in urban and rural minority populations. Asthma continues to place a heavy burden on patients and their families as well as the health-care system. In an attempt to respond to the need for well-designed clinical trials to allow rapid evaluation of new and existing therapeutic approaches for asthma and for dissemination of laboratory and clinical findings to the health-care community, the Division of Lung Diseases, National Heart, Lung, and Blood Institute, established the Asthma Clinical Research Network.
UR - http://www.scopus.com/inward/record.url?scp=0035212563&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035212563&partnerID=8YFLogxK
U2 - 10.1016/s0197-2456(01)00161-1
DO - 10.1016/s0197-2456(01)00161-1
M3 - Review article
C2 - 11728618
AN - SCOPUS:0035212563
SN - 0197-2456
VL - 22
SP - S119-S125
JO - Controlled Clinical Trials
JF - Controlled Clinical Trials
IS - 6 SUPPL. 1
ER -